Rindone Joseph P, Mellen Chadwick K
Clinical Pharmacy Section, Northern Arizona VA Health Care System, Hwy 89, Prescott, AZ 86313, United States.
Curr Drug Saf. 2018;13(2):141-143. doi: 10.2174/1574886313666180219165742.
Salsalate may offer many advantages over other non-steroidal antiinflammatory agents in patients taking warfarin, however a drug-drug interaction may occur which has not been reported in the medical literature or by the manufacturer of salsalate.
To report a case of warfarin potentiation associated with salsalate treatment, which resulted in bleeding.
Clinical review of the course of a patient, who was stable on warfarin when salsalate therapy was added for chronic pain.
A patient taking stable doses of warfarin for over 1 year (with good control) was prescribed salsalate 3 g/day for pain in his knee and lower back. Approximately 1 month later he presents to the anticoagulation clinic with bruising and an International Normalized Ratio (INR) of 6.8. The patient had a good response to his salsalate therapy and wanted to continue it. The warfarin was held for 3 days and dose lowered by 50 %. His bruising then subsided and he had good control of his warfarin therapy with INRs ranging from 1.9 to 2.2 over the next 4 months. The patient was then lost to follow up.
This case illustrates a strong association between starting salsalate and subsequent potentiation of warfarin, which heretofore has not been reported in the medical literature.
